Hong Kong da Phnom Penh, Cambodia, Yuni 22, 2021 / PRNewswire/ - Ma'aikatar Lafiya ta Kambodiya ta amince da sayar da gwajin gwajin antigen na INDICAID® COVID-19 a matsayin wani bangare na kokarin kasar na shawo kan karuwar karuwar COVID-19 na baya-bayan nan. lokuta .
Gwamnatin Cambodia ta tura gwaje-gwajen antigen cikin sauri kamar INDICAID® don gudanar da gwaje-gwaje masu yawa a Phnom Penh babban birnin kasar da yankunan da ke kewaye, ta yin amfani da gajeren lokaci da saukaka sakamakon gwajin don taimakawa gwamnati cikin sauri gano masu cutar COVID-19 tare da dakile cutar. yaduwar cutar.Waɗannan gwaje-gwajen kuma sun haifar da ingantattun matakan ɗaukar hoto, tare da rarraba babban birnin zuwa wuraren ja, orange, da rawaya yadda ya kamata dangane da adadin lokuta da haɗarin watsawa.Hakanan ana iya siyar da INDICAID® a cikin Phnom Penh.
Ricky Chiu, wanda ya kafa kuma Shugaba na PHASE Scientific, ya ce: "Mun yi imanin cewa daidaito, sauƙi na amfani da kuma araha na kayan gwajin mu zai sa INDICAID® ta taka muhimmiyar rawa a aikin tantancewa da gwamnatin Cambodia ke gudanarwa a yankin.Role."Kamfanin ƙera kayan gwajin INDICAID® na hukuma."Muna maraba da shawarar da gwamnatin Cambodia ta yanke kuma muna fatan yin amfani da kayan gwajin mu cikin sauri don tallafawa kasashen makwabta."
Chiu ya bayyana cewa kasashe da yawa sun karɓi INDICAID® don yaƙar COVID-19.A Hong Kong inda PHASE Scientific ke da hedkwata, INDICAID® gwamnati ta amince da shi a matsayin samfurin da aka keɓe don ziyarar asibiti da gidan jinya.Ita ce mafi kyawun siyarwa a tsakanin samfuran makamantanta kuma ta sayar da kayan fiye da miliyan 2.Hakanan asibitoci, kamfanoni na gwamnati da masu zaman kansu, manyan kantuna, otal-otal da makarantu suna karbe shi sosai don tantancewar gida da waje.
INDICAID® COVID-19 Gwajin Antigen Rapid Antigen alama ce ta CE-lakabin immunoassay na gefe wanda aka ƙera don gano ƙimar SARS-CoV-2 antigen a cikin samfuran swab na hanci kai tsaye.Tare da ingantaccen ingancin samfur da sauƙin amfani, INDICAID® na iya samar da sakamako da sauri a cikin mintuna 20, ba tare da buƙatar kayan aiki ko wurare na musamman ba.An tabbatar da daidaiton wannan kayan gwajin a asibiti a cikin mafi girman gwaji na asibiti na duniya, wanda aka gwada INDICAID® akan PCR a cikin samfuran sama da 9,200 kuma ya nuna hankali da ƙayyadaddun bayanai.
INDICAID® a halin yanzu yana cikin ƙasashe 33 kuma yana kan aiwatar da samun izinin amfani da gaggawa (EUA) daga Hukumar Abinci da Magunguna ta Amurka (FDA).
Marubuci: John Vandermosten, CFA TSX: PMN.TO |OTC: ARFXF |NASDAQ: BIIB Ɗaya daga cikin mahaukata mafi hazaƙa a fannin fasahar kere-kere ita ce tatsuniyar aducanumab da ta faru a cikin ƴan shekarun da suka gabata.Aducanumab, tare da alamar kasuwanci Aduhelm, rigakafi ne na amyloid-directed monoclonal don maganin cutar Alzheimer (AD).Aduhelm yana ɗaure da tarin amyloid kuma yana da
Kamfanin Cantex Pharmaceuticals Inc.Bisa ga yarjejeniyar, Cantex zai dauki nauyin haɓakawa da kuma sayar da azeliragon, kuma kamfanonin biyu za su rarraba ribar da ke ƙasa a karkashin tsarin tsari.Ba a bayyana wasu bayanan kuɗi ba.“Saboda haka, akwai damar haɓaka azeliragon, tsarin sarrafa magungunan baka na kashi 2
Kasuwancin iyali mai ɗorewa ya ƙunshi mahimman abubuwan nasara guda huɗu waɗanda ke haɓaka haɗin kan iyali, haɓaka kasuwanci da adana dukiya na dogon lokaci.
Mawallafi: Dr. David Bautz Nasdaq: MNOV Karanta cikakken rahoton bincike na MNOV Sabuntawar kasuwanci MN-166 Mataki na 2 tabbatacce sakamakon gwajin dalar Australiya Yuni 21, 2021, MediciNova, Inc. (NASDAQ: MNOV) Sanar da sakamako mai kyau na Mataki na 2 An buga gwajin MN-166 (Ibudilast) a cikin Rashin Amfani da Barasa (AUD) a cikin littafin Nature Translational Psychiatry (Grodin et al., 2021).Gwaji ne a
Duniya ta yarda da allurar rigakafin mura tare da inganci wanda bai wuce 50% ba, don haka ingantattun kayayyaki na iya sake fasalin kasuwa da yuwuwar faɗaɗa kasuwa.
(Bloomberg) - Jami'an kiwon lafiya na New Zealand suna zage-zage don gano abokan huldar wani matafiyi dan kasar Australia daga Sydney wanda ya ziyarci Wellington a karshen mako kuma ya kamu da cutar ta Covid-19.Ganin cewa wannan mataki na iya sa masu shirya gasar Olympics ta Tokyo yin watsi da shirin sayar da barasa a wuraren, Kyodo News ta ruwaito cewa ya taimaka wajen yaduwar cutar, amma ba shi da wani mallaka.Yayin da jami'ai ke nuna damuwa game da bullar sabbin bambance-bambancen, China na shirin kiyaye takunkumin tafiye-tafiye na akalla wata shekara.Fadar White House ta amince
Shigar da sabbin matakai 10 na rayuwa, ku tuna kafa ƙafa akan kariyar tunani don shirye-shiryen ku.www.vhis.gov.hk Duba shi!
Bayan barkewar cutar sankara da yawa a kusa da makarantar, Isra'ila ta ba da shawarar yin allurar rigakafi ga matasa, har ma da cikakken alurar riga kafi na iya kamuwa da cutar saboda hukumomi suna zargin bambance-bambancen Delta mai yaduwa.Kasar ta ba da rahoton bullar cutar guda 125 cikin sa'o'i 24 a ranar Talata, mafi girman jimillar kwana guda tun karshen watan Afrilu.Bayan gwajin bazuwar, an sami sabon barkewar cutar a makarantu da yawa, kuma bayan Isra'ila ta ɗaga kusan duk takunkumin coronavirus
'Yar wani ma'aikaciyar gundumar da ba a yi wa allurar rigakafi ba a Florida ta mutu bayan COVID-19 ta ratsa ginin ofishin gwamnati inda ta yi aiki.Ta ce ita da danginta sun ki amincewa a yi musu allurar, duk da cewa abokiyar aikin mahaifiyarsu da aka yi wa allurar ba ta da lafiya ko kadan.Babu wani a cikin iyalina da ke samun allurar rigakafi," Molly Hart ta shaida wa Daily Beast.Mahaifiyar Hart, Mary Knight, 58, ta mutu sakamakon rikice-rikice masu alaƙa da COVID-19 a makon da ya gabata, Tabbatar da Identity County Manatee
A cikin binciken Phase 2/3 wanda Makarantar Magunguna ta Jami'ar Washington ke jagoranta, gwajin rigakafin anti-amyloid na Eli Lilly da Kamfanin (NYSE: LLY) da Roche Holdings (OTC: RHHBY) sun kasa inganta Al Symptoms na cutar Zheimer (AD) ).shekara.Yanzu, masu bincike sun ce suna da shaidar cewa Roche's gantenerumab na iya taimakawa wasu marasa lafiya.Daga cikin mahalarta gwaji a cikin Ciwon Cutar Alkawari (DIAD), Roche's
Rangwamen ƙaramin tsari na No.1: Zaɓuɓɓukan farashin ƙasa 5 [$0 zuwa $75000], tare da inshorar likitancin kamfanin don kashe inshorar don jin daɗin kariyar shekara-shekara na miliyan 30.
Babban Asibitin Yahudawa (JGH) memba ne na Cibiyar Kiwon Lafiya ta Midwwest na Montreal (CIUSSS) kuma shine farkon wanda ya shiga Auger Groupe Conseil Inc. (AGC) da Medtronic Canada ULC (reshen Medtronic (NYSE: MDT)) Yi amfani da Microsoft HoloLens don ainihin-lokaci, tsawaita gaskiya (XR) tallafi na asibiti don ƙaramin aikin tiyata na zuciya.
Dokta Susannah Hills, Likitan Jirgin Sama na Yara kuma Mataimakiyar Farfesa na Otolaryngology a Cibiyar Kiwon Lafiya ta Jami'ar Columbia, ta shiga Yahoo Finance don tattauna sabbin labarai game da cutar sankara.
Lokacin da masu bincike suka kalli dabi'ar marijuana na rukunin mutane tsakanin shekaru 18 zuwa 30, wani binciken shekaru 25 daga baya ya wuce hazo.
Hotunan da Pixaby Biotechnology ya bayar sun kasance tushen wasu mahimman binciken likita a duniya a cikin 'yan shekarun nan.Yawancin ci gaban da aka samu, gami da allurar COVID-19, fasahar sa ido kan annoba, da bankunan halittu, sun fito ne daga farawa da ƙananan kamfanoni.Akwai dubban irin waɗannan farawa a fagen fasahar kere-kere.Ruhinsu na majagaba da saurin daidaitawa sun sanya waɗannan kamfanoni a cikin babban matsayi a cikin masana'antar ilimin halittu.Ga wasu
Mongolia ta yi wa mutanenta alkawarin "Rani ba tare da Covid-19" ba.Bahrain ta ce "za ta koma rayuwa ta yau da kullun."Karamar tsibirin Seychelles na da burin fara tattalin arzikinta.Dukkanin ukun sun yi imani da akalla zuwa wani mataki a cikin saukin samun alluran rigakafin da ake yi a kasar Sin, wanda zai ba su damar kaddamar da manyan shirye-shiryen rigakafin cutar yayin da ba a samu su a yawancin sassan duniya ba.Koyaya, duk ƙasashen uku yanzu suna yaƙi da hauhawar kamuwa da cuta maimakon kawar da coronavirus.rajista
UniQure NV (NASDAQ: QURE) ta sanar da bayanan makonni 52 na etranacogene dezaparvovec don maganin hemophilia B a cikin gwajin jiyya na HOPE-B na 3.Bayanai sun nuna cewa makonni 52 bayan jiyya na hemophilia B, aikin factor IX (FIX) ya ci gaba da karuwa.A lokacin bin makonni na 26, matsakaicin aikin FIX da aka shigar shine 41.5% na ƙimar al'ada, kuma matsakaicin aikin FIX shine 39% na ƙimar al'ada.FIX wani furotin ne da aka samar a cikin jiki, wanda ke taimakawa jini ya samar da gudan jini don dakatar da zubar jini.A cikin waɗannan makonni 52, guda ɗaya
Fauci ya kara da cewa "Albishir: rigakafin mu yana da tasiri a kan bambance-bambancen Delta."“Wannan bambance-bambancen yana wakiltar tsarin maye gurbi wanda zai iya haifar da maye gurbi da ke guje wa rigakafin mu a nan gaba.Wannan shine dalilin da ya sa a yanzu alluran rigakafi sun fi tasiri fiye da kowane lokaci.Lokaci ya fi mahimmanci don dakatar da sarkar kamuwa da cuta - sarkar maye gurbi wanda zai iya haifar da sauye-sauye masu haɗari, "in ji Rochelle Walensky, darektan Cibiyar Kula da Cututtuka da Cututtuka (CDC).Bambancin Delta ya haifar da mummunar barkewar COVID-19 a Indiya a cikin Afrilu da Mayu, wanda ya mamaye ayyukan kiwon lafiyar kasar tare da haddasa mutuwar daruruwan dubban.
Kamfanin fasahar kere-kere na kasar Jamus BioNTech SE (BNTX) ya bayyana cewa a gwajinsa na mataki na biyu na rigakafin cutar kansa na BNT111 don ci gaban cutar melanoma, an ba wa mara lafiya na farko maganin.BioNTech majagaba ne a cikin rigakafin rigakafi don ciwon daji, cututtuka da sauran cututtuka na yau da kullun.Kamfanin yana da faffadan fakiti na ƴan takarar maganin ƙari, magungunan maye gurbin furotin, ƙananan ƙwayoyin ƙwayoyin cuta, ƙwayoyin rigakafi na zamani da kuma hanyoyin kwantar da hankali.Kashi na biyu na gwaji yana nazarin ingancin gudanarwa na BNT111
Wani sabon binciken da aka buga a JAMA ya gano cewa maza 45 da suka karɓi maganin COVID-19 mRNA ba su da bambance-bambance a cikin sigogin maniyyi.Magungunan mRNA guda biyu masu izini waɗanda Pfizer da Moderna suka haɓaka sune mafi yawan amfani da rigakafin COVID-19 a cikin Amurka.Masu bincike a makarantar likitanci ta Miller a jami'ar Miami sun ce sun fara binciken ne bayan jin damuwar wasu..An yi imani cewa allurar rigakafi na iya shafar haihuwa.Sun nuna cewa wannan binciken yana da wasu iyakoki
Atai Life Sciences (NASDAQ: ATAI) ya fara halarta a NASDAQ ranar Juma'a.Kamfanin na Berlin zai shiga ƙungiyar farawa ta musamman a cikin masana'antar tunani kuma za a jera su akan NASDAQ a wannan shekara, gami da MindMed (NASDAQ: MNMD) da Hanyoyin Komputa (NASDAQ) Code: CMPS).Tare da goyon bayan Peter Thiel, wanda ya kafa PayPal (NASDAQ: PYPL), kamfanin ya tara fiye da dala miliyan 362 a kudade tun lokacin da aka kafa a 2018. Atai ya kara dalar Amurka miliyan 225 a farkon kyautar jama'a a ranar Alhamis.
Dokta Ron Friedman, masanin ilimin zamantakewar al'umma kuma marubucin littafin "Decoding the Great," ya gaya wa Yahoo Finance Live cewa sauye-sauyen da cutar ta COVID-19 ta haifar za ta haifar da "juyi a yadda kungiyoyi ke aiki."
Lokacin aikawa: Juni-23-2021